About: De Los Pulsos De Corticoides En Pacientes Con Síndrome De Liberación De Citoquinas Inducido Por Infección Por Sars-Cov-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: De Los Pulsos De Corticoides En Pacientes Con Síndrome De Liberación De Citoquinas Inducido Por Infección Por Sars-Cov-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	De Los Pulsos De Corticoides En Pacientes Con Síndrome De Liberación De Citoquinas Inducido Por Infección Por Sars-Cov-2
Creator	Luis, José De, Juan Castillo, Del Centeno, Norberto Centeno, Ortego Colmenero Ruiz E -Norberto, Arrabal D -Manuel De La, Javier De, España Fernández C -, Hera Fernández, Hera Guirao, Emilio Luis, Autores -José Luis, Correspondencia -Jose Luna, Dios Manuel, Arrabal Rubio, Callejas Ruiz, Colmenero
Source	Elsevier; Medline; PMC; WHO
abstract	Abstract Introduction: cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19. Patients: we included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable. Results: in all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival. Discussion: the early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death.
has issue date	2020-05-27(xsd:dateTime)
bibo:doi	10.1016/j.medcli.2020.04.018
bibo:pmid	32532461
has license	els-covid
sha1sum (hex)	5f40cd8f0b397c2abcf506356803565fd9363466
schema:url	https://doi.org/10.1016/j.medcli.2020.04.018
resource representing a document's title	De Los Pulsos De Corticoides En Pacientes Con Síndrome De Liberación De Citoquinas Inducido Por Infección Por Sars-Cov-2
has PubMed Central identifier	PMC7250763
has PubMed identifier	32532461
schema:publication	Med Clin (Barc)
resource representing a document's body	covid:5f40cd8f0b397c2abcf506356803565fd9363466#body_text
is schema:about of	named entity 'PULSES' named entity 'CYTOKINE STORM' named entity 'TITLE' named entity 'SARS-CoV-2' named entity 'CORTICOID' named entity 'SARS-CoV-2' named entity 'CYTOKINE STORM SYNDROME' named entity 'virus' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'intubation' named entity 'tocilizumab' named entity 'SARS' named entity 'IL-6' named entity 'cytokine storm' named entity 'son la' named entity 'corticosteroids' named entity 'hazard ratio' named entity 'cytokine storm syndrome' named entity 'requerimiento' named entity 'macrophage activation syndrome' named entity 'SARS-CoV-2' named entity 'HFS' named entity 'IL-6' named entity 'COVID-19' named entity 'iniciales' named entity 'CSS' named entity 'tocilizumab' named entity 'tabla' named entity 'como' named entity 'tocilizumab' named entity 'tabla' named entity 'MAS' named entity 'hemophagocytic syndrome' named entity 'SARS-CoV-2' named entity 'PCR' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'PCR' named entity 'PCR' named entity 'CSS' named entity 'tocilizumab' named entity 'ello' named entity 'IL-6' named entity 'tocilizumab' named entity 'CSS' named entity 'SARS-CoV2' named entity 'COVID' named entity 'tocilizumab' named entity 'como' named entity 'Stata' named entity 'statistical significance' named entity 'COVID' named entity 'el método' named entity 'claves' named entity 'la respuesta' named entity 'PCR' named entity 'COVID' named entity 'COVID' named entity 'coronavirus' named entity 'tocilizumab' named entity 'como' named entity 'cytokine release syndrome' named entity 'covid-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software